- Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million and 25% YoY for the full year to $271 million.
- LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.
- Overall, LUPKYNIS sales accounted for about 96% of the company’s total revenue in Q4 and for the full year 2025.
Aurinia Pharmaceuticals Inc. (AUPH) shares gained nearly 4% in Thursday’s pre-market trade after the company posted a fourth-quarter (Q4) earnings and revenue beat.
Aurinia reported adjusted earnings per share (EPS) of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.
However, the company’s 2026 revenue guidance fell short of Wall Street expectations. Aurinia guided for revenue in the range of $315 million and $325 million during the year, but the consensus estimate stood at $326.8 million.
Retail sentiment on Stocktwits around Aurinia Pharmaceuticals trended in the ‘bullish’ territory, with message volumes at ‘high’ levels. The stock was among the top three trending tickers on the platform at the time of writing.
Active Lupus Nephritis Therapy Sales Gain Momentum
Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million. For the full year, LUPKYNIS sales stood at $271 million, rising 25% YoY.
LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.
Overall, LUPKYNIS sales contributed to about 96% of the company’s total revenue in Q4 as well as the full year 2025.
Aurinia also stated that the full-year revenue includes a $10 million milestone payment received by the company following the approval of LUPKYNIS by regulators in Japan.
How Did Stocktwits Users React?
One user called Aurinia’s earnings and cash position “solid.”
Another user called Aurinia’s numbers “excellent,” saying they’re excited for the company's long-term shareholders.
AUPH stock is down 10% year-to-date, but up 80% over the past 12 months.
Also See: CELH Stock Is Soaring Pre-Market Today — What Is Driving The Surge?
For updates and corrections, email newsroom[at]stocktwits[dot]com.